As tezepelumab awaits FDA decision, Amgen and AstraZeneca tout more data from the Phase III study

As AstraZeneca and Amgen’s Dupixent challenger awaits a decision by the FDA, the companies are touting new data they hope could bolster their case.

Researchers revealed additional results from a pivotal Phase III trial for AstraZeneca and Amgen’s tezepelumab over the weekend, studying the treatment in severe, uncontrolled asthma. In...

Click to view original post